Fabry's Disease
9
0
0
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.1%
1 terminated out of 9 trials
85.7%
-0.8% vs benchmark
11%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain
Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)
Early Detection and Follow-Up of Patients With Fabry's Disease
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease
Fabry's Disease and Pregnancy (PREFAB)
Analysis of the Nervous System in Patients With Fabry's Disease
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains